David Campany-Herrero

6PUBLICATIONS
16CO-AUTHORS
Haematological tumoursIndustrial microbiology (incl. biofeedstocks)Medical bacteriologyMedical infection agents (incl. prions)Environmental epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 04, 2025
Effectiveness of Electrocautery, Topical Cidofovir, and Topical Sinecatechins for the Treatment of Anal High-Grade Squamous Intraepithelial Lesions in Persons With HIV: An Open-Label, Randomized Controlled Trial.

Joaquin Burgos, Adrià Curran, Jorge Garcia

|Jan 25, 2025
Correction: Kirkegaard-Biosca et al. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. Antibiotics 2024, 13, 874.

Cristina Kirkegaard-Biosca, Ester Del Barrio-Tofiño, Miguel Villamarín

|Jan 08, 2025
Ciprofloxacin for the Treatment of Infections Caused by Carbapenemase-Producing Gram-Negative Bacteria.

Pablo Rubiñan, Belén Viñado, Nuria Fernández-Hidalgo

|Sep 28, 2024
Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria.

Cristina Kirkegaard-Biosca, Ester Del Barrio-Tofiño, Miguel Villamarín

|May 12, 2023
Ertapenem blood concentration: A retrospective cohort study to analyse risk of neurotoxicity.

David Campany-Herrero, Alba Pau-Parra, Pablo González-Moreno

|Jun 07, 2020
Tigecycline-associated hypofibrinogenemia in a real-world setting.

David Campany-Herrero, Maria Larrosa-Garcia, Pilar Lalueza-Broto

Pageof 1